Tag: Al amyloidosis

Over the last decade, there has been a significant expansion in the number of FDA-approved drugs for amyloidosis, with distinct treatments now available for different types of the disease. The answer to **What drugs are FDA approved for amyloidosis?** depends on whether a patient has transthyretin (ATTR) or light chain (AL) amyloidosis, as the treatments for each type differ substantially.

An estimated 4,000 people develop primary amyloidosis in the U.S. each year, a rare disease that has seen a recent surge in treatment options [1.10.3]. So, what is the new drug for amyloidosis? The answer depends on the type, with several groundbreaking therapies approved in late 2023 and 2024 [1.3.1, 1.4.1].